Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
The aim of this study is to evaluate the clinical efficacy and safety of continuous Endostar infusion combined with radiotherapy for treatment of brain metastases.
Brain Metastases
RADIATION: 6MV-X ray|DRUG: Endostar
Objective Response Rate (ORR), 1 month after initial treatment
Overall Survival, 2 year|Serum VEGF Levels, at baseline and 1 month after initial treatment|VEGF levels in tumor tissue, at baseline and 1 month after initial treatment|Incidence of Adverse Events, up to 1 month after last dose|Cerebral Edema, 1 month after initial treatment
The aim of this study is to evaluate the clinical efficacy and safety of continuous Endostar infusion combined with radiotherapy for treatment of brain metastases.